Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...

CVS sees 23% revenue growth in healthcare benefits & projects 10% EPS in 2025, with Aetna recovery boosting performance.

Successful launches of biosimilars to HUMIRA and STELARA are key revenue drivers. Alvotech’s business-to-business model facilitates global reach, with one-third of revenues from ex-U.S. markets.